<DOC>
	<DOCNO>NCT00730769</DOCNO>
	<brief_summary>The objective study : 1 . To demonstrate efficacy/safety short therapeutic strategy treatment CMV infection/disease SOT patient ( kidney , liver heart recipient ) base 21 day treatment . 2 . To compare exposure ganciclovir , steady state , oral valganciclovir respect ganciclovir give intravenously ( i.v. ) . 3 . Evaluate security treatment valganciclovir .</brief_summary>
	<brief_title>Valganciclovir Treatment Cytomegalovirus Infection Solid Organ Transplant Patients</brief_title>
	<detailed_description>SOT recipient ( kidney , liver heart transplant ) present CMV infection disease eligible inclusion ≥18 year age present positive CMV antigenemia ( pp65 ) define ≥ 20positive cells/105 peripherical blood mononuclear cell ( PBMC ) . Patients exclude severe CMV tissue invasive disease , unable receive oral medication , absolute neutrophil count less 500/ mm3 , platelet &lt; 25000 platelets/mm3 , Hemoglobin &lt; 80g/l estimate glomerular filtration rate &lt; 10 mL/min ( accord Cockcroft-Gault formula ) . Patients receive short induction treatment ganciclovir i.v ( Cymevene® ; F. Hoffmann-La Roche Ltd , Basel , Switzerland ) dose 5 mg/kg/12h , peripherical vein infusion one hour , 5 day follow treatment oral valganciclovir ( Valcyte® ; F. Hoffmann-La Roche Ltd , Basel , Switzerland ) 900 mg/12h 16 day , meal , complete total 21 day treatment . In patient impaired renal function ganciclovir i.v . oral valganciclovir dos adjust visit accord estimate Glomerular Filtration Rate ( GFR ) Cockcroft-Gault equation , recommend manufacturer .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>≥18 year age , solid organ transplant recipient . present CMV infection demonstrate CMV antigenemia ( pp65 ) define ≥ 20positive cells/105 peripherical blood mononuclear cell ( PBMC ) . give write informed consent . HIV patient . Multiorganic transplant . Severe CMV tissue invasive disease . Unable receive oral medication . absolute neutrophil count less 500/ mm3 . Platelets &lt; 25000 platelets/mm3 . Hemoglobin &lt; 80g/l . Estimated glomerular filtration rate &lt; 10 mL/min ( accord CockcroftGault formula )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Valganciclovir</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Solid organ transplantation</keyword>
	<keyword>Transplant</keyword>
</DOC>